Integra Lifesciences (NASDAQ:IART) Cut to “Sell” at ValuEngine

ValuEngine cut shares of Integra Lifesciences (NASDAQ:IART) from a hold rating to a sell rating in a research report sent to investors on Thursday, ValuEngine reports.

Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of Integra Lifesciences from a hold rating to a buy rating in a research report on Saturday, July 27th. Wells Fargo & Co upped their price target on shares of Integra Lifesciences from $55.00 to $68.00 and gave the stock a market perform rating in a research report on Thursday, July 25th. Oppenheimer upped their price target on shares of Integra Lifesciences from $65.00 to $70.00 and gave the stock an outperform rating in a research report on Thursday, July 25th. BTIG Research set a $70.00 price target on shares of Integra Lifesciences and gave the stock a buy rating in a research report on Wednesday, July 24th. Finally, JMP Securities upped their price target on shares of Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $61.92.

Shares of IART traded down $1.04 during mid-day trading on Thursday, reaching $62.38. The stock had a trading volume of 265,927 shares, compared to its average volume of 394,491. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of 25.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.08. Integra Lifesciences has a 12 month low of $42.14 and a 12 month high of $66.41. The business’s fifty day moving average price is $55.79. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.08. The business had revenue of $383.60 million during the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 earnings per share. As a group, equities analysts anticipate that Integra Lifesciences will post 2.73 earnings per share for the current fiscal year.

In related news, Director Christian S. Schade sold 15,658 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $51.56, for a total transaction of $807,326.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Kenneth Burhop sold 6,656 shares of the company’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $63.98, for a total transaction of $425,850.88. Following the transaction, the vice president now owns 15,921 shares of the company’s stock, valued at approximately $1,018,625.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,844 shares of company stock valued at $2,085,117. 4.50% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of IART. Swiss National Bank raised its stake in shares of Integra Lifesciences by 2.1% in the second quarter. Swiss National Bank now owns 134,794 shares of the life sciences company’s stock valued at $7,528,000 after acquiring an additional 2,800 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Integra Lifesciences by 6.7% in the second quarter. Envestnet Asset Management Inc. now owns 47,240 shares of the life sciences company’s stock valued at $2,638,000 after acquiring an additional 2,946 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Integra Lifesciences in the second quarter valued at $500,000. CWM LLC grew its holdings in shares of Integra Lifesciences by 724,466.7% in the second quarter. CWM LLC now owns 86,948 shares of the life sciences company’s stock worth $4,856,000 after purchasing an additional 86,936 shares during the last quarter. Finally, Olstein Capital Management L.P. bought a new position in shares of Integra Lifesciences in the second quarter worth about $447,000. Hedge funds and other institutional investors own 82.18% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: What are the disadvantages of after-hours trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.